Adaptin Bio (APTN) Non-Current Assets (2024)
Adaptin Bio's (APTN) quarterly Non-Current Assets came in at $193876.0 in Q4 2024.
Powered by 
Analysis
Adaptin Bio (APTN) Non-Current Assets (2024) Analysis & Trends
Adaptin Bio has disclosed Non-Current Assets across 1 years of filings, most recently posting $193876.0 for Q4 2024.
- In Q4 2024, Non-Current Assets changed N/A year-over-year to $193876.0; the TTM figure through Sep 2025 stood at $193876.0 (changed N/A YoY), while the FY2024 annual figure was $193876.0, changed N/A from the prior year.
- Non-Current Assets came in at $193876.0 for Q4 2024 at Adaptin Bio.
- In the past five years, Non-Current Assets ranged from a high of $193876.0 in Q4 2024 to a low of $193876.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 441.00 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 279.00 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 451.27 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 523.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 150.83 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 207.76 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 35.91 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 964.69 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 238.14 Mn |
| 10 | Adaptin Bio | 56.76 Mn | 56.09 Mn | - | - |